Opendata, web and dolomites

PMSMatTrain SIGNED

Novel Biomaterial-based Device for the Treatment of Progressive MS- - An Integrated Pan- European Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PMSMatTrain project word cloud

Explore the words cloud of the PMSMatTrain project. It provides you a very rough idea of what is the project "PMSMatTrain" about.

property    april    small    intellectual    affairs    spectrophotometry    tool    basics    molecules    followed    industry    entrepreneurship    oligodendrocyte    training    cross    medical    neuroprotection    time    cns    disease    stage    cgmp    innovation    functionalised    biomaterials    pms    hyaluronan    signals    elusion    modal    jrtp    release    manufacturing    mechanisms    regulatory    organotypic    tested    evaluation    silico    joint    miconazole    axonal    compulsory    scaffolds    skills    transferable    directed    leadership    clinically    stem    education    complementary    translation    mri    drugs    discipline    demyelination    vivo    cell    gender    recruited    degenerative    commercialisation    immediately    modifying    patient    sclerosis    cortex    gaining    designed    mass    spif    pmsmattrain    scaled    therapy    policy    smes    device    molecular    beneficiaries    biomimetic    utilise    progressive    ibudilast    employable    proximal    pathophysiology    dispersal    arising    generate    chronic    receive    drug    inflammatory    neuroinflammation    talk    anti    first    multiple    standardised    model    neuroprotective    quality    yield    remyelination    esrs    weight    protocols    cultures    ms    characterised   

Project "PMSMatTrain" data sheet

The following table provides information about the project.

Coordinator
NATIONAL UNIVERSITY OF IRELAND GALWAY 

Organization address
address: UNIVERSITY ROAD
city: Galway
postcode: H91
website: www.nuigalway.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙962˙143 €
 EC max contribution 3˙962˙143 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2023-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) coordinator 1˙373˙421.00
2    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 512˙640.00
3    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) participant 505˙576.00
4    NEOS SURGERY SL ES (DONOSTIA SAN SEBASTIAN) participant 501˙809.00
5    SYDDANSK UNIVERSITET DK (ODENSE M) participant 297˙522.00
6    UNIVERSITE GRENOBLE ALPES FR (GRENOBLE) participant 274˙802.00
7    UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA IT (CHIETI) participant 261˙499.00
8    CONTIPRO AS CZ (DOLNI DOBROUC) participant 234˙871.00
9    UNIVERSITE GRENOBLE ALPES FR (SAINT MARTIN D'HERES) participant 0.00

Map

 Project objective

PMSMatTrain is focusing on gaining a comprehensive understanding of the progressive (late degenerative phase) of multiple sclerosis (PMS) from basics to translation, fully supported by 8 beneficiaries (6 research institutions, 2 SMEs). Recruited ESRs will receive compulsory discipline-specific, generic and complementary transferable skills training. PMSMatTrain’s Joint Research Education and Training programme (JRTP) will provide early stage researchers with high quality research and transferable skills training in intellectual property, leadership skills, innovation, regulatory affairs, entrepreneurship, gender policy, and medical device evaluation, which will ensure that they are immediately employable in industry. The consortium will develop a multi-modal hyaluronan-based medical device designed to release small molecular weight anti-inflammatory molecules (APRIL and sPIF) followed by remyelination and neuroprotective drugs (ibudilast and miconazole). PMSMatTrain will for the first time utilise these functionalised multi-modal biomimetic hyaluronan scaffolds as a tool to investigate cross-talk between signals arising due to chronic neuroinflammation and those leading to demyelination and axonal loss, while identifying molecular mechanisms that facilitate remyelination and neuroprotection in PMS. This approach could yield the first cortex-proximal and directed biomaterials-based disease-modifying therapy for PMS. These scaffolds will be tested in state of the art MS patient induced stem cell-derived oligodendrocyte cultures and organotypic cultures to investigate MS pathophysiology. In vivo responses will be characterised using field-leading MRI and mass spectrophotometry protocols. PMSMatTrain will also generate a clinically-relevant in silico model of drug elusion and dispersal within the CNS. Our industry partners will develop the end-device by providing standardised manufacturing protocols for scaled-up production and commercialisation of the cGMP product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PMSMATTRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PMSMATTRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

HeatNMof (2020)

Heating triggered drug release from nanometric inorganic-metal organic framework composites

Read More